140 related articles for article (PubMed ID: 33019983)
1. Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for therelative efficacy of tamoxifen and aromatase inhibitors.
Gershenson DM; Cobb LP; Sun CC
Gynecol Oncol; 2020 Dec; 159(3):601-603. PubMed ID: 33019983
[No Abstract] [Full Text] [Related]
2. PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
Tang M; O'Connell RL; Amant F; Beale P; McNally O; Sjoquist KM; Grant P; Davis A; Sykes P; Mileshkin L; Moujaber T; Kennedy CJ; deFazio A; Tan K; Antill Y; Goh J; Bonaventura T; Scurry J; Friedlander M
Gynecol Oncol; 2019 Sep; 154(3):531-538. PubMed ID: 31227223
[TBL] [Abstract][Full Text] [Related]
3. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.
Gershenson DM; Sun CC; Iyer RB; Malpica AL; Kavanagh JJ; Bodurka DC; Schmeler K; Deavers M
Gynecol Oncol; 2012 Jun; 125(3):661-6. PubMed ID: 22406638
[TBL] [Abstract][Full Text] [Related]
4. A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer.
Jager W; Sauerbrei W; Beck E; Maassen V; Stumpfe M; Meier W; Kuhn W; Janicke F
Anticancer Res; 1995; 15(6B):2639-42. PubMed ID: 8669839
[No Abstract] [Full Text] [Related]
5. Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors.
Stanley B; Hollis RL; Nunes H; Towler JD; Yan X; Rye T; Dawson C; Mackean MJ; Nussey F; Churchman M; Herrington CS; Gourley C
Gynecol Oncol; 2019 Feb; 152(2):278-285. PubMed ID: 30501904
[TBL] [Abstract][Full Text] [Related]
6. Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis.
Paleari L; Gandini S; Provinciali N; Puntoni M; Colombo N; DeCensi A
Gynecol Oncol; 2017 Sep; 146(3):504-513. PubMed ID: 28705409
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
Schmeler KM; Sun CC; Bodurka DC; Deavers MT; Malpica A; Coleman RL; Ramirez PT; Gershenson DM
Gynecol Oncol; 2008 Mar; 108(3):510-4. PubMed ID: 18155273
[TBL] [Abstract][Full Text] [Related]
8. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas.
Ordóñez NG
Hum Pathol; 2005 Nov; 36(11):1163-7. PubMed ID: 16260268
[TBL] [Abstract][Full Text] [Related]
9. Estrogen and progesterone receptors in breast cancer.
Ma CX
Clin Adv Hematol Oncol; 2011 May; 9(5):385-6. PubMed ID: 21685867
[No Abstract] [Full Text] [Related]
10. Current advances in endocrine therapy options for premenopausal women with hormone receptor positive breast cancer.
Gemignani ML; Hetzel DJ
Gynecol Oncol; 2017 Oct; 147(1):153-157. PubMed ID: 28662774
[No Abstract] [Full Text] [Related]
11. The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.
George A; McLachlan J; Tunariu N; Della Pepa C; Migali C; Gore M; Kaye S; Banerjee S
BMC Cancer; 2017 Jun; 17(1):456. PubMed ID: 28666422
[TBL] [Abstract][Full Text] [Related]
12. Clinical response to antiestrogen therapy in platinum-resistant ovarian cancer patients and the role of tumor estrogen receptor expression status.
Stasenko M; Plegue M; Sciallis AP; McLean K
Int J Gynecol Cancer; 2015 Feb; 25(2):222-8. PubMed ID: 25500503
[TBL] [Abstract][Full Text] [Related]
13. Endocrine therapy in epithelial ovarian cancer.
Langdon SP; Gourley C; Gabra H; Stanley B
Expert Rev Anticancer Ther; 2017 Feb; 17(2):109-117. PubMed ID: 27967255
[TBL] [Abstract][Full Text] [Related]
14. Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study.
Ferreira AR; Palha A; Correia L; Filipe P; Rodrigues V; Miranda A; André R; Fernandes J; Gouveia J; Passos-Coelho JL; Moreira A; Brito M; Ribeiro J; Metzger-Filho O; Lin NU; Costa L; Vaz-Luis I
Breast; 2018 Feb; 37():107-113. PubMed ID: 29131988
[TBL] [Abstract][Full Text] [Related]
15. Pattern of endocrine treatment for epithelial ovarian cancer in the Southeast medical region of Sweden: a population-based study.
Bagge E; Beiron U; Malander S; Rosenberg P; Åvall-Lundqvist E
Acta Oncol; 2019 Mar; 58(3):320-325. PubMed ID: 30632888
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy is of Value in Second Line and Beyond, Relapsed High-grade, Serous Epithelial Ovarian Cancer: An Analysis of Outcomes Obtained With Oral Etoposide.
Kumar A; Le N; Santos J; Hoskins P
Am J Clin Oncol; 2018 Apr; 41(4):379-384. PubMed ID: 26999277
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer.
Karagol H; Saip P; Uygun K; Caloglu M; Eralp Y; Tas F; Aydiner A; Topuz E
Med Oncol; 2007; 24(1):39-43. PubMed ID: 17673810
[TBL] [Abstract][Full Text] [Related]
18. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
[TBL] [Abstract][Full Text] [Related]
19. Primary papillary serous carcinoma of the peritoneum: report of a case with diagnosis by fine needle aspiration and immunocytochemistry.
Alberti N; Serrano-Egea A; García-García E; Ballestín C; Pérez-Barrios A; López-Ríos F; de Agustín P
Acta Cytol; 2007; 51(2):203-6. PubMed ID: 17425204
[TBL] [Abstract][Full Text] [Related]
20. Aromatase inhibition in relapsing low malignant potential serous tumours of the ovary.
Esfahani K; Ferrario C; Le P; Panasci L
BMJ Case Rep; 2014 Jun; 2014():. PubMed ID: 24925537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
